Ref: Syn/CS/SE/PR/September 2018 - 031

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099, India
T +91 80 6775 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937

www.syngeneintl.com

September 25, 2018

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Subject: Press Release

This has reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Please find enclosed the press release titled **"Notice of management change".**

The above mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

MAYANK VERMA
Digitally signed by MAYANK VERMA
Date: 2018.09.25 08:50:47 +05'30'

Mayank Verma
Company Secretary



Notice of management change

25th September 2018

Syngene International Ltd., a leading global contract research service provider, today announced that Dr. Manoj Nerurkar, Chief Operating Officer, will step down from his role with effect from 1st Oct 2018 and the announcement of the appointment of his successor will be made shortly.

Dr. Nerurkar will continue his association with Syngene, taking a new strategic advisory role focussed on innovation across Syngene's services, in addition to pursuing an external start up opportunity outside of contract research services.

Kiran Mazumdar Shaw, Managing Director said "Manoj has played a key role in establishing Syngene among the world's leading Discovery and Development Services CROs. Throughout his tenure, he has actively engaged in developing the next generation of leadership talent as well as ensuring we have established world class infrastructure and capabilities. His proven track record of building successful businesses through a focus on innovation and world class delivery will hold him in good stead in the future. I wish him the very best in his business endeavours."

Jonathan Hunt, Chief Executive Officer commented "During his nine years as Chief Operating Officer, Manoj has made a pivotal contribution to Syngenes success; playing a central role in scaling the organisation, building world class capabilities and establishing a strong R&D leadership team as well steering the company through a successful IPO. I know both colleagues and clients will miss their day to day interactions with him, at the same time, I look forward to working with him in his new strategic advisory role and wish him great success with his new business venture."

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), an innovation focused global discovery, development and manufacturing organization provides integrated services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries across the world. Syngene's clientele include market leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Zoetis, Merck KGaA and Herbalife. Its innovative culture is driven by a strong team of over 3500 scientists working with clients around the world to improve R&D productivity, while reducing development time and cost. For more details, visit www.syngeneintl.com.



Contact details

Investor Contact	**Media Contact**
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com